德国生物技术研发商Actithera宣布完成A轮融资，由多家知名投资机构联合投资。

Along the eastern shore of Hudson Bay in Canada’s northeastern province of Quebec, near the Inuit municipality of Inukjuak, ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

But finding geological evidence of the extent of Earth's life (that is, locating rocks that formed with Earth, not on it) is ...

Earth formed about 4.6 billion years ago, during the geological eon known as the Hadean. The name “Hadean” comes from the ...